Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin
- 1 October 2001
- Vol. 58 (4) , 578-582
- https://doi.org/10.1016/s0090-4295(01)01293-6
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- SAFETY AND EFFICACY OF AN IMPLANTABLE LEUPROLIDE DELIVERY SYSTEM IN PATIENTS WITH ADVANCED PROSTATE CANCERJournal of Urology, 2000
- AN IMPLANT RELEASING THE GONADOTROPIN HORMONE-RELEASING HORMONE AGONIST HISTRELIN MAINTAINS MEDICAL CASTRATION FOR UP TO 30 MONTHS IN METASTATIC PROSTATE CANCERJournal of Urology, 2000
- Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancerUrology, 1999
- Subcutaneous hydrogel reservoir system for controlled drug deliveryMacromolecular Symposia, 1996
- Treatment of Advanced Prostatic CancerUrologic Clinics of North America, 1987
- Effect of an LHRH agonist on pituitary and testicular function in rhesus monkeysReproduction, 1984